REVEL PHARMACEUTICALS INC.
Enzymatic assay kit using proprietary oxidase enzyme to measure advanced glycation and lipoxidation end products (AGE/ALEs) in biological samples
Follows are private to you and power your alerts
Updated · revelpharmaceuticals.com
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Founded
- 2019
- Latest Form D
- $5.8M, Mar 2022
- Total capital
- $10M
- Federal grants
- $2.9M
- 6 awards · 2023–2025
- Rank in peer group#22 of 42
- Private capital raised
- $7.1M
- 3 Form D · last Mar 2022
- 55 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts$1.4M
- Federal grantHealth and Human S · Phase I · Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy$358K
- Federal grantHealth and Human S · Phase I · An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts$347K
- Federal grantHealth and Human S · Phase I · Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease$324K
- Federal grantHealth and Human S · Phase I · Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts$278K
- Federal grantHealth and Human S · Phase I · An enzyme-based assay for the detection of acetaldehyde-protein adducts$272K
- Private capital raisedForm D · SEC · 3rd filing$5.8M
- Private capital raisedForm D · SEC · 2nd filing$800K
- Private capital raisedForm D · SEC · 1st filing$533K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 42 peers
Line = medianBiotech · Instrument
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Aaron James CravensResearcherExecutive Officer, DirectorLinked by $2.7M in grants as PI
- Jennifer James CochranDirectorNamed in SEC Form D filings
- Patrick James BurgermeisterDirectorNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- Expansion Technologies, Inc.Similar federal contract value in Biotech · null in contracts
- Peel Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
- Rgenta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- ADRX, INC.Similar federal contract value in Biotech · null in contracts
- TRANSCODE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- 1910 GENETICS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .